Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 29, 2013

View Archived Issues

Alnylam Pharmaceuticals divulges new siRNAs for bleeding disorders

Sepsis and aging studied in Drosophila model

Interim data presented for FG-3019 in patients with PDAC

KLF6 gene variant is strongly associated with breast cancer metastasis

Interim data from phase I RRx-001 study available

Preliminary phase I results presented for golvatinib plus sorafenib in HCC

Merck KGaA designs novel FSH receptor agonists

Chinese researchers disclose new SGLT2 inhibitors

Abbott presents new PDE10A inhibitors

Shanghai Institute of Materia Medica synthesizes new PLA2 inhibitors

Newron Pharmaceuticals patents new sodium and/or calcium channel blockers

Ipca Laboratories prepares new platelet adhesion inhibitors

First patient treated in GCS-100 phase I/II trial

Zerenex meets primary and secondary endpoints in phase III trial

Hanmi Pharmaceutical finds partner to market esomeprazole strontium

EC approves BindRen for hyperphosphatemia

Companies collaborate on combination studies of simeprevir, TMC-647055 and IDX-719

SP-333 advances into phase Ib study

Chugai seeks Japanese approval of trastuzumab emtansine

Charleston Laboratories begins phase III trial of CL-108

Dipraglurant shows promise in rodent model of dystonia

Protein S100-A10 has prognostic significance in pancreatic cancer

Grants supports The Scripps Research Institute's research on ASK-1

Phase III program of latanoprostene bunod begins

Delay to topline results from first pivotal study of Androxal

ReNeuron advances PISCES study of ReN-001 stem cell therapy for stroke

MolecularMD obtains license to LKB1 use in NSCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...